Frequency Therapeutics is a technology company.
Frequency Therapeutics has raised $42.0M across 1 funding round.
Frequency Therapeutics has raised $42.0M in total across 1 funding round.
Frequency Therapeutics is a clinical-stage biopharmaceutical company that develops regenerative medicines aimed at restoring lost sensory function, primarily focusing on hearing loss. Its flagship product, FX-322, uses progenitor cell activation (PCA) technology to stimulate the body's own cells to regenerate damaged inner ear tissue, addressing sensorineural hearing loss, a condition with limited treatment options. The company serves patients with hearing impairment and is expanding its regenerative approach into other therapeutic areas, supported by ongoing clinical trials and strategic partnerships[1][3].
Founded in 2014 and headquartered in Lexington, Massachusetts, Frequency Therapeutics was established to harness the body's natural regenerative potential through innovative cell activation technology. The idea emerged from scientific advances in progenitor cell biology, aiming to create therapies that stimulate tissue repair rather than relying on external cell transplants. Early clinical trials of FX-322 demonstrated promising results, marking pivotal moments that validated the company's approach and attracted investor interest[1][2].
Frequency Therapeutics rides the growing trend of regenerative medicine and precision biologics, which aim to repair or replace damaged tissues at the cellular level. The timing is favorable due to advances in cell biology, increased investment in biotech innovation, and a rising prevalence of sensory disorders in aging populations. Market forces such as unmet clinical needs in hearing loss and degenerative diseases create strong demand for novel therapies. Frequency’s work influences the broader ecosystem by advancing progenitor cell activation as a viable therapeutic strategy, potentially opening new avenues in regenerative medicine[1][3].
Frequency Therapeutics is positioned to potentially transform treatment for hearing loss and other degenerative conditions through its PCA platform. The next critical milestones include successful late-stage clinical trial results and regulatory approvals for FX-322. Trends shaping its journey include advances in regenerative biology, growing healthcare focus on sensory impairments, and increasing biotech funding. If successful, Frequency could expand its influence by validating progenitor cell activation as a new therapeutic paradigm, attracting further research and investment in this space[1][3].
In summary, Frequency Therapeutics combines cutting-edge science with a clear clinical focus on sensory restoration, aiming to address significant unmet medical needs through innovative regenerative therapies.
Frequency Therapeutics has raised $42.0M in total across 1 funding round.
Frequency Therapeutics's investors include Axil Capital.
Frequency Therapeutics has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series B in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $42.0M Series B | Axil Capital |